The identification of a number of psoriasis-susceptibility genes and a better understanding of the pathogenesis of the intracellular metabolic pathways, have generated new perspectives on psoriasis treatment, in particular new compounds that inhibit certain intracellular proteins involved in the immune response. In contrast to biologic agents, these compounds block intracellular targets such as transcriptional factors or enzymes. AREAS COVERED: Tofacitinib is a small molecule that acts as a reversible, competitive inhibitor of ATP in the ATP binding site of JAK proteins, determining their inactivation, thus prevents the downstream activation of the STAT proteins, which are then unable to up-regulate the pro-inflammatory genes implicated in psoriasis. The authors present an overview of Phases I - III clinical trials of tofacitinib for psoriasis based on peer-reviewed literature. EXPERT OPINION: In clinical practice, it is important to assess the response of psoriasis to tofacitinib and identify possible clinical, genetic, and immune biomarkers to predict the response. Comorbidities associated with psoriasis, in particular metabolic syndrome and obesity, are also an important aspect of using tofacitinib in clinical practice. There are some evidences that a drug such as tofacitinib could be used to improve not only psoriasis, but also some of its important comorbidities.
Galluzzo, M., D'Adamio, S., Servoli, S., Bianchi, L., Chimenti, S., & Talamonti, M. (2016). Tofacitinib for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 17(10), 1421-1433 [10.1080/14656566.2016.1195812].
|Tipologia:||Articolo su rivista|
|Citazione:||Galluzzo, M., D'Adamio, S., Servoli, S., Bianchi, L., Chimenti, S., & Talamonti, M. (2016). Tofacitinib for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 17(10), 1421-1433 [10.1080/14656566.2016.1195812].|
|Settore Scientifico Disciplinare:||Settore MED/35 - Malattie Cutanee e Veneree|
|Revisione (peer review):||Esperti anonimi|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/14656566.2016.1195812|
|Stato di pubblicazione:||Pubblicato|
|Data di pubblicazione:||2016|
|Titolo:||Tofacitinib for the treatment of psoriasis|
|Autori:||Galluzzo, M; D'Adamio, S; Servoli, S; Bianchi, L; Chimenti, S; Talamonti, M|
|Appare nelle tipologie:||01 - Articolo su rivista|